We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Prostate Cancer Detected in Blood Using Flow Cytometry

By LabMedica International staff writers
Posted on 22 Feb 2016
Current methods of detecting prostate cancer, such as the prostate-specific antigen (PSA) test and biopsies, have limitations. More...
PSA tests are based on measuring a specific protein released by the prostate gland, but do not provide a definitive diagnosis.

A physical exam and biopsy are needed if PSA levels are elevated; however, even the painful biopsy procedure has a 15% error rate. During biopsies, a painful and invasive procedure, 12 needles are inserted into the rectum, with the hope of extracting material from an area with a tumor.

A team of scientists at the Western University's Schulich School of Medicine and Dentistry (London, ON, Canada) and at Lawson Health Research Institute (London, ON, Canada) have repurposed a machine once used to detect airborne pathogens in the second Gulf War. The machine is now used for fluid biopsies, a noninvasive way to detect prostate microparticles in the blood in a matter of minutes. Microparticles are essentially refuse released by prostate cells that circulate throughout the bloodstream.

The machine was used in the Gulf War, and more commonly to test water purity and the machine uses flow cytometry (Apogee Flow Systems; Hemel Hempstead, UK) to detect microparticles. Flow cytometry measures the specific characteristics of a fluid, such as blood, as it passes through a laser. Most men, who are more than 40 years old, regardless of their health, have detectable levels of prostate microparticles in their bloodstream. The scientists have conducted the first clinical cancer project to correlate the number of microparticles in the blood to the risk of having prostate cancer in that the more microparticles, the higher the risk.

The study provides a more accurate and less invasive testing method for patients suspected of having prostate cancer, and helps to identify patients who are at a higher risk of dying from prostate cancer. Hon Leong, PhD, an assistant professor and team leader, said, “Our findings point to a new direction in how we can better identify patients who actually have prostate cancer. With this test, we can improve the clinical outcomes for patients, reducing costs for unnecessary procedures and reducing errors in diagnosis.”

Related Links:

Western University's Schulich School of Medicine and Dentistry
Lawson Health Research Institute
Apogee Flow Systems



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.